| |
Significant patient populations, top clinical institutions, and ease of
regulatory compliance combined to support oncology trial success in APAC. Download our white paper to explore the growth of oncology trials in APAC countries and strategies to support global study success in this dynamic and complex region. Premier Research. Built for Biotech℠ 
|
|
Today's Big NewsOct 27, 2022 |
| By Max Bayer Merck is dropping the cancer treatment acquired in its acquisition of Viralytics back in 2018. A spokesperson confirmed that the asset was axed as a part of the company's prioritization efforts. |
|
|
|
By Nick Paul Taylor GSK has dumped one of its top pipeline prospects. While two of the three phase 3 trials of otilimab hit their primary endpoints, the Big Pharma concluded the efficacy fell short of the level needed to take the anti-GM-CSF antibody forward in rheumatoid arthritis. |
By Nick Paul Taylor Bristol Myers Squibb has inked a multi-year extension to its collaboration with Obsidian Therapeutics, securing itself the exclusive option to license cell therapies that use its partner’s technology to control the expression of CD40L. |
By James Waldron DiaMedica Therapeutics’ Remedy 2 trial remains on clinical hold after the FDA requested more data to allay its concerns about how the potential stroke drug is administered intravenously. |
By Gabrielle Masson Bluebird spinout 2seventybio and China-based CAR-T company JW Therapeutics are joining forces to build out a cell therapy platform in hopes of creating T cell receptor therapies for certain solid tumors. |
By Fraiser Kansteiner Genentech on Thursday said Vabysmo aced its endpoints in a pair of phase 3 studies—BALATON and COMINO—that pitted the drug against Regeneron and Bayer’s Eylea in patients with macular edema due to branch and central retinal vein occlusion, respectively. |
By Andrea Park In recent years, 23andMe has repositioned itself as a genetic testing company that does more than help users fill out their family trees, but also answer crucial questions about their predispositions for potential conditions. |
By Ben Adams Pfizer and Moderna have launched their COVID-19 booster campaigns this fall and now so too has the U.S. government, though it has a specific focus on getting through to Black and Hispanic communities with a series of new TV and radio ads. |
By Dave Muoio The Franklin, Tennessee-based hospital operator’s overall dip to $3.12 billion net operating revenue was hindered by slipping inpatient volumes and a 1.7% year-over-year increase in total operating costs. |
By Zoey Becker Following two FDA rejections of novel oral anemia drugs, all eyes are on GSK’s daprodustat. Now, the drug has come out of an FDA panel meeting partially bruised, losing experts' support in one of the two patient populations that it’s seeking approval for. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we talk about our special report on the top 10 vaccine company rankings. We also report the news on Pfizer's kickback lawsuit, OTC hearing aids and more. |
|
|---|
|
|
|
Wednesday, November 2, 2022 | 1pm ET / 10am PT This webinar will discuss how Invitae and others are working together to characterize the lived experience of patients with rare bile duct cancer, and ultimately, improve patient care. Register now. 
|
|
eBook Improve patient engagement, adherence, and outcomes Sponsored by: Health Catalyst |
Whitepaper Electronic health records (EHR) and patient registries are both important sources of real-world evidence – but which is right for your needs? Sponsored by: Veradigm Health |
eBook Looking to implement a remote patient monitoring (RPM) program at your organization? Download the eBook from Health Catalyst to learn the essential components of successful RPM programs. Sponsored by: Health Catalyst |
eBook In this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities. Sponsored by: RCH Solutions |
eBook With real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy. Sponsored by: Optum |
Whitepaper Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem. Sponsored by: NTT DATA |
Whitepaper SaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security. Sponsored by: LabVantage Solutions Inc. |
Whitepaper Read about key factors and trends in RWE and how our data luminaries are the right partner to lead the way forward. Sponsored by: Lumanity |
Whitepaper This paper is the first in a 4-part series focused on developing commercial models for gene therapies Sponsored by: Blue Matter, strategic consultants in the life sciences |
Video Learn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
Video Can an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent |
| |
|
